KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement

Annals of Hematology

Volumn 92, Issue 2, 2013, Pages 163-171

  Kim, Hee Je ^k   Kim, Hee Jin ^a   Ahn, Hee Kyung ^a   Jung, Chul Won ^a   Moon, Joon Ho ^b   Park, Chang Hun ^a   Lee, Ki O ^c   Kim, Sun Hee ^a   Kim, Yeo Kyeoung ^d   Kim, Hyeoung Joon ^d   Sohn, Sang Kyun ^b   Kim, Sung Hyun ^e   Lee, Won Sik ^f   Kim, Kyoung Ha ^g   Mun, Yeung Chul ^h   Kim, Hawk ⁱ   Park, Jinny ^j   Min, Woo Sung ^k   Kim, Dong Hwan Dennis ^a,l  

^a Sungkyunkwan University   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Samsung Medical Center   (South Korea)

^d Chonnam National University   (South Korea)

^e Dong A University   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Soonchunhyang University   (South Korea)

^h Ewha Womans University School of Medicine   (South Korea)

ⁱ University of Ulsan   (South Korea)

^j Gachon University College of Medicine   (South Korea)

^k The Catholic University of Korea   (South Korea)

^l UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Core binding factor positive acute myeloid leukemia; KIT; Korea; Mutation

Indexed keywords

CORE BINDING FACTOR; CORE BINDING FACTOR BETA; CYTARABINE; ENOCITABINE; IDARUBICIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CBFB GENE; CONTROLLED STUDY; ETHNIC GROUP; EVENT FREE SURVIVAL; FEMALE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; INDEL MUTATION; KOREAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYH11 GENE; NUCLEOTIDE SEQUENCE; ONCOGENE C KIT; OVERALL SURVIVAL; PRIORITY JOURNAL; RUNX1 GENE; RUNX1T1 GENE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME INVERSION; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; COMBINED MODALITY THERAPY; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORE BINDING FACTORS; CYTARABINE; DISEASE-FREE SURVIVAL; EXONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDARUBICIN; KAPLAN-MEIER ESTIMATE; KOREA; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POINT MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872345873     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1580-5     Document Type: Article

References (14)

1. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083
2. Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H (1992) Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80:1825-1831
3. Liu P, Tarle SA, Hajra A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS (1993) Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 261:1041-1044
4. Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 23:5705-5717
5. Schlenk RF, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Dohner K, Ganser A, Dohner H, Heil G (2004) Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22:3741-3750
6. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine O, Quesnel B, Baruchel A, Leverger G, Dombret H, Preudhomme C (2006) Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20:965-970
7. Care RS, Valk PJ, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort WM, Wilson GA, Gari MA, Peake IR, Lowenberg B, Reilly JT (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 121:775-777
8. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L, Morra E (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107:3463-3468
9. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, Schoch C (2006) KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107:1791-1799
10. Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y (2006) KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 107:1806-1809
11. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911
12. Luck SC, Russ AC, Du J, Gaidzik V, Schlenk RF, Pollack JR, Dohner K, Dohner H, Bullinger L (2010) KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. Br J Haematol 148:925-937
13. Lee DH, Chung NG, Cho B, Kim HK, Kang HJ, Shin HY, Ahn HS, Yoo KH, Sung KW, Koo HH, Kook H, Hwang TJ, Im HJ, Seo JJ, Park HJ (2010) Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea. J Korean Med Sci 25:9-15
14. Mitelman F (1995) ISCN 1995: an International System for Human Cytogenetic Nomenclature (1995). Karger, Basel